# OnCo record lutetium-177-therapy-home-radiation-safety (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/lutetium-177-therapy-home-radiation-safety/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "lutetium-177-therapy-home-radiation-safety" ;
  schema:name "Radiation safety at home after lutetium-177 PSMA or dotatate therapy"@en ;
  schema:alternateName "Pluvicto radiation precautions"@en, "Lutathera radiation precautions"@en, "177Lu-PSMA home precautions"@en, "PRRT home precautions"@en, "radioligand therapy precautions"@en, "after lutetium treatment at home"@en, "radiation safety after radionuclide therapy"@en ;
  schema:description "After a lutetium-177 treatment your body gives off a small amount of radiation for some days, and most of the radioactivity leaves in your urine. For a short time you are asked to keep some distance from others, especially children and anyone pregnant, to sleep apart, to be careful with the toilet and washing, and to drink plenty. Your team will give you written instructions with the exact days."@en ;
  schema:url <https://onco.cc/protocols/lutetium-177-therapy-home-radiation-safety/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/neuroendocrine/> ;
  onco:technologies <https://onco.cc/technologies/lu177-radioligand-therapy/> ;
  onco:drugs <https://onco.cc/drugs/pluvicto/>, <https://onco.cc/drugs/lutathera/> ;
  onco:terms <https://onco.cc/terms/castration-resistance/> .